Savara (SVRA) Competitors $3.47 +0.04 (+1.17%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$3.48 +0.01 (+0.29%) As of 10/8/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SVRA vs. BLTE, IBRX, ARQT, RXRX, MESO, IRON, AGIO, DNLI, SRPT, and ETNBShould you be buying Savara stock or one of its competitors? The main competitors of Savara include Belite Bio (BLTE), ImmunityBio (IBRX), Arcutis Biotherapeutics (ARQT), Recursion Pharmaceuticals (RXRX), Mesoblast (MESO), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), Sarepta Therapeutics (SRPT), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. Savara vs. Its Competitors Belite Bio ImmunityBio Arcutis Biotherapeutics Recursion Pharmaceuticals Mesoblast Disc Medicine Agios Pharmaceuticals Denali Therapeutics Sarepta Therapeutics 89BIO Belite Bio (NASDAQ:BLTE) and Savara (NASDAQ:SVRA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability. Which has better earnings & valuation, BLTE or SVRA? Belite Bio is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelite BioN/AN/A-$36.14M-$1.55-50.36SavaraN/AN/A-$95.88M-$0.50-6.94 Do insiders & institutionals have more ownership in BLTE or SVRA? 0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, BLTE or SVRA? Belite Bio has a beta of -1.46, meaning that its stock price is 246% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Does the media refer more to BLTE or SVRA? In the previous week, Savara had 30 more articles in the media than Belite Bio. MarketBeat recorded 32 mentions for Savara and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.80 beat Savara's score of 0.06 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Savara 1 Very Positive mention(s) 3 Positive mention(s) 26 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend BLTE or SVRA? Belite Bio currently has a consensus target price of $96.00, indicating a potential upside of 22.98%. Savara has a consensus target price of $7.50, indicating a potential upside of 116.14%. Given Savara's stronger consensus rating and higher probable upside, analysts clearly believe Savara is more favorable than Belite Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Belite Bio 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Savara 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Is BLTE or SVRA more profitable? Belite Bio's return on equity of -34.90% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets Belite BioN/A -34.90% -33.56% Savara N/A -69.05%-54.84% SummarySavara beats Belite Bio on 8 of the 13 factors compared between the two stocks. Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVRA vs. The Competition Export to ExcelMetricSavaraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$592.83M$2.64B$6.10B$10.55BDividend YieldN/A56.71%5.69%4.75%P/E Ratio-6.9423.6985.4727.60Price / SalesN/A556.27582.22224.03Price / CashN/A173.2337.9261.55Price / Book3.475.5313.136.76Net Income-$95.88M$32.78M$3.30B$275.88M7 Day Performance-0.57%5.82%4.29%2.81%1 Month Performance-9.16%13.16%9.45%9.24%1 Year Performance-4.93%1.69%86.64%35.42% Savara Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVRASavara2.7093 of 5 stars$3.47+1.2%$7.50+116.1%-8.2%$592.83MN/A-6.9420Trending NewsAnalyst ForecastBLTEBelite Bio2.8575 of 5 stars$78.10+3.3%$96.00+22.9%+44.8%$2.41BN/A-50.3910Positive NewsAnalyst ForecastIBRXImmunityBio2.6429 of 5 stars$2.53-0.4%$10.75+324.9%-28.1%$2.40B$14.74M-5.27590ARQTArcutis Biotherapeutics1.3742 of 5 stars$19.76-0.8%$19.80+0.2%+119.4%$2.39B$196.54M-26.35150RXRXRecursion Pharmaceuticals1.8391 of 5 stars$5.53+0.7%$7.25+31.1%-5.4%$2.38B$58.84M-3.11400News CoverageAnalyst ForecastOptions VolumeMESOMesoblast1.7979 of 5 stars$17.32-5.9%$24.00+38.6%+106.8%$2.36B$17.20M0.0080Analyst ForecastGap UpIRONDisc Medicine2.3656 of 5 stars$69.28+2.2%$98.30+41.9%+46.7%$2.36BN/A-15.5030Analyst ForecastAGIOAgios Pharmaceuticals4.5192 of 5 stars$40.89+1.0%$56.00+37.0%+5.2%$2.35B$36.50M3.72390Analyst DowngradeDNLIDenali Therapeutics4.2875 of 5 stars$15.22-1.3%$33.50+120.1%-41.5%$2.25BN/A-5.44430Analyst ForecastSRPTSarepta Therapeutics4.5836 of 5 stars$23.26+2.7%$39.32+69.0%-80.5%$2.21B$1.90B-26.741,372Analyst ForecastETNB89BIO3.1027 of 5 stars$14.87+0.1%$25.81+73.6%+99.9%$2.20BN/A-4.1240Analyst Forecast Related Companies and Tools Related Companies BLTE Alternatives IBRX Alternatives ARQT Alternatives RXRX Alternatives MESO Alternatives IRON Alternatives AGIO Alternatives DNLI Alternatives SRPT Alternatives ETNB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVRA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
